Selective CHK1 inhibitor MU380 exhibits single-agent activity
against chronic lymphocytic leukemia cells with TP53 mutations

a 2018

Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations

BOUDNÝ, Miroslav; Jana ZEMANOVÁ; PrashantKumar KHIRSARIYA; Marek BORSKÝ; Jan VERNER et. al.

Basic information

Original name

Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations

Authors

BOUDNÝ, Miroslav (203 Czech Republic, belonging to the institution); Jana ZEMANOVÁ (203 Czech Republic, belonging to the institution); PrashantKumar KHIRSARIYA (356 India, belonging to the institution); Marek BORSKÝ (203 Czech Republic, belonging to the institution); Jan VERNER (203 Czech Republic, belonging to the institution); Jana ČERNÁ (203 Czech Republic, belonging to the institution); Marek MRÁZ (203 Czech Republic, belonging to the institution); Alexandra OLTOVÁ (203 Czech Republic, belonging to the institution); Zuzana JAŠKOVÁ (703 Slovakia, belonging to the institution); Michaela ŠPUNAROVÁ (203 Czech Republic, belonging to the institution); Václav ŠEDA (203 Czech Republic, belonging to the institution); Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution); Jiří MAYER (203 Czech Republic, belonging to the institution); Kamil PARUCH (203 Czech Republic, belonging to the institution) and Martin TRBUŠEK (203 Czech Republic, guarantor, belonging to the institution)

Edition

23rd Congress of the European Hematology Association, Stockholm, Sweden in HemaSphere, 2018

Other information

Language

English

Type of outcome

Conference abstract

Field of Study

10606 Microbiology

Confidentiality degree

is not subject to a state or trade secret

RIV identification code

RIV/00216224:14110/18:00104533

Organization unit

Faculty of Medicine

Keywords in English

CHK1; MU380; CLL; TP53

Changed: 2/5/2019 14:23, Soňa Böhmová

Abstract

V originále

Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations, Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations.

Links

MUNI/A/0968/2017, interní kód MU

Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit V (Acronym: VýDiTeHeMA V)

Investor: Masaryk University, Category A

NV15-33999A, research and development project

Name: Vývoj nových nízkomolekulárních protinádorových léčiv na principu syntetické letality

Cite

BOUDNÝ, Miroslav; Jana ZEMANOVÁ; PrashantKumar KHIRSARIYA; Marek BORSKÝ; Jan VERNER; Jana ČERNÁ; Marek MRÁZ; Alexandra OLTOVÁ; Zuzana JAŠKOVÁ; Michaela ŠPUNAROVÁ; Václav ŠEDA; Yvona BRYCHTOVÁ; Jiří MAYER; Kamil PARUCH and Martin TRBUŠEK. Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations. In 23rd Congress of the European Hematology Association, Stockholm, Sweden in HemaSphere. 2018.

@proceedings{1469384,
   author = {Boudný, Miroslav and Zemanová, Jana and Khirsariya, PrashantKumar and Borský, Marek and Verner, Jan and Černá, Jana and Mráz, Marek and Oltová, Alexandra and Jašková, Zuzana and Špunarová, Michaela and Šeda, Václav and Brychtová, Yvona and Mayer, Jiří and Paruch, Kamil and Trbušek, Martin},
   booktitle = {23rd Congress of the European Hematology Association, Stockholm, Sweden in HemaSphere},
   keywords = {CHK1; MU380; CLL; TP53},
   language = {eng},
   title = {Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations},
   year = {2018}
}

TY  - CONF
ID  - 1469384
AU  - Boudný, Miroslav - Zemanová, Jana - Khirsariya, PrashantKumar - Borský, Marek - Verner, Jan - Černá, Jana - Mráz, Marek - Oltová, Alexandra - Jašková, Zuzana - Špunarová, Michaela - Šeda, Václav - Brychtová, Yvona - Mayer, Jiří - Paruch, Kamil - Trbušek, Martin
PY  - 2018
TI  - Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations
KW  - CHK1
KW  - MU380
KW  - CLL
KW  - TP53
N2  - Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations, Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations.
ER  -

BOUDNÝ, Miroslav; Jana ZEMANOVÁ; PrashantKumar KHIRSARIYA; Marek BORSKÝ; Jan VERNER; Jana ČERNÁ; Marek MRÁZ; Alexandra OLTOVÁ; Zuzana JAŠKOVÁ; Michaela ŠPUNAROVÁ; Václav ŠEDA; Yvona BRYCHTOVÁ; Jiří MAYER; Kamil PARUCH and Martin TRBUŠEK. Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations. In \textit{23rd Congress of the European Hematology Association, Stockholm, Sweden in HemaSphere}. 2018.

Přehled o publikaci